Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

NCT00728390

CompletedPhase 1

Sponsor: Pfizer

Conditions: Carcinoma, Non-Small Cell, Neoplasm Metastasis

Interventions: PF-00299804

Countries: United States, France, Spain

This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 0-1;
* Platelets \> 100,000, ANC \> 1500;
* Ccr \> 60 or serum creat. \<1.5
* Non-small cell cancer cohort:
* Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, \< 4 prior chemotherapy regimen
* HgA1C \<5.7%

Exclusion Criteria:

* Active Central Nervous System (CNS) metastases;
* prior IGF1-R targeted therapy
* Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.
Locations (5)
  • Amherst, New York, United States
  • Buffalo, New York, United States
  • San Antonio, Texas, United States
  • Villejuif, France
  • Madrid, Spain